Probenecid: An emerging tool for neuroprotection

CNS and Neurological Disorders - Drug Targets

Volumn 12, Issue 7, 2013, Pages 1050-1065

  Colín González, Ana Laura ^a,b   Santamaría, Abel ^a  

^a NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Clinical perspectives; Neurological disorders; Neuroprotective mechanisms; Neurotransmitter modulation; Pharmacokinetics; Probenecid

Indexed keywords

ABC TRANSPORTER; AMINOPHYLLINE; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; AROMATIC HYDROCARBON RECEPTOR; AZAPROPAZONE; BENZODIAZEPINE DERIVATIVE; CHLOROTHIAZIDE DERIVATIVE; ENTACAPONE; FAMOTIDINE; KYNURENIC ACID; LOOP DIURETIC AGENT; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN; MYCOPHENOLIC ACID; NITROFURANTOIN; NONSTEROID ANTIINFLAMMATORY AGENT; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 3; PARACETAMOL; PEMETREXED; PENICILLIN DERIVATIVE; PHENYLACETIC ACID; PRALATREXATE; PROBENECID; QUINOLONE DERIVATIVE; SULFONYLUREA; THEOPHYLLINE DERIVATIVE; UNINDEXED DRUG; VANILLOID RECEPTOR 2;

ABDOMINAL CRAMP; ALZHEIMER DISEASE; ANAPHYLAXIS; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; ANTIOXIDANT ACTIVITY; APLASTIC ANEMIA; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BRAIN ISCHEMIA; CHOLINERGIC STIMULATION; CLINICAL FEATURE; COMPETITIVE INHIBITION; DRUG ACTIVITY; DRUG MECHANISM; DYSPNEA; EPILEPSY; FEVER; GASTROINTESTINAL SYMPTOM; GENETIC TRANSCRIPTION; GOUT; HEADACHE; HUMAN; HUNTINGTON CHOREA; HYPERSENSITIVITY; LEUKOPENIA; LIVER NECROSIS; MIGRAINE; MYALGIA; NAUSEA AND VOMITING; NEPHROLITHIASIS; NEPHROTIC SYNDROME; NEUROLOGIC DISEASE; NEUROPROTECTION; NEUROTRANSMITTER RELEASE; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; RASH; SCHIZOPHRENIA; VASOMOTOR DISORDER;

ANIMALS; BRAIN; DRUG INTERACTIONS; HUMANS; KYNURENINE; MODELS, NEUROLOGICAL; NERVOUS SYSTEM DISEASES; NEUROPROTECTIVE AGENTS; PROBENECID; SIGNAL TRANSDUCTION;

EID: 84888995418     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/18715273113129990090     Document Type: Article

References (139)

1. Burnell, J.M.; Kirby, W.M. Effectiveness of a new compound, benemid, in elevating serum penicillin concentrations. J. Clin. Invest., 1951, 30, 697-700.
2. Boger, W.P.; Beatty, J.O.; Pitts, F.; Flippin, H.F. The influence of a new benzoic acid derivative on the metabolism of para-aminosalicylic acid (PAS) and penicillin. Ann. Intern. Med., 1950, 33, 18-31.
3. Gutman, J; Kachur, S. P.; Slutsker, L; Nzila, A.; Mutabingwa, T. Combination of probenecid-sulphadoxine-pyrimethamine for intermittent preventive treatment in pregnancy. Malar. J., 2012, 11, 39.
4. Talbott, J. H. Clinical and metabolic effects of benemid in gout. Bull. Rheum. Dis., 1951, 2, 1-2.
5. Robbins, N.; Koch, S. E.; Tranter, M.; Rubinstein, J. The history and future of probenecid. Cardiovasc. Toxicol., 2012, 12, 1-9.
6. Graves, W.K.; Neff, R.; Mark, P. Altered glucose metabolism in pregnancy: its determination and fetal outcome. Trans. Pac. Coast Obstet. Gynecol. Soc., 1966, 34, 20-26.
7. Di Virgilio, F.; Fasolato, C.; Steinberg, T. H. Inhibitors of membrane transport system for organic anions block fura-2 excretion from PC12 and N2A cells. Biochem. J., 1988, 256, 959-963.
8. Di Virgilio, F.; Steinberg, T. H.; Swanson, J. A.; Silverstein, S. C. Fura-2 secretion and sequestration in macrophages. A blocker of organic anion transport reveals that these processes occur via a membrane transport system for organic anions. J. Immunol., 1988, 140, 915-920.
9. Yabuuchi, H.; Tamai, I.; Morita, K.; Kouda, T.; Miyamoto, K.; Takeda, E.; Tsuji, A. Hepatic sinusoidal membrane transport of anionic drugs mediated by anion transporter Npt1. J. Pharmacol. Exp. Ther., 1998, 286, 1391-1396.
10. Sweet, D. H.; Wolff, N. A.; Pritchard, J. B. Expression cloning and characterization of ROAT1. The basolateral organic anion transporter in rat kidney. J. Biol. Chem., 1997, 272, 30088-30095.
11. Gollapudi, S.; Kim, C. H.; Tran, B. N.; Sangha, S.; Gupta, S. Probenecid reverses multidrug resistance in multidrug resistance-associated protein-overexpressing HL60/AR and H69/AR cells but not in P-glycoprotein-overexpressing HL60/Tax and P388/ADR cells. Cancer Chemother. Pharmacol., 1997, 40, 150-158.
12. Packham, M. A.; Rand, M. L.; Perry, D. W.; Ruben, D. H.; Kinlough-Rathbone, R. L. Probenecid inhibits platelet responses to aggregating agents in vitro and has a synergistic inhibitory effect with penicillin G. Thromb. Haemost., 1996, 76, 239-44.
13. Bang, S.; Kim, K. Y.; Yoo, S.; Lee, S. H.; Hwang, S. W. Transient receptor potential V2 expressed in sensory neurons is activated by probenecid. Neurosci. Lett., 2007, 425, 120-125.
14. Davoren, P. R.; Sutherland, E. W. The effect of L-epinephrine and other agents on the synthesis and release of adenosine 3', 5'-phosphate by whole pigeon erythrocytes. J. Biol. Chem., 1963, 238, 3009-30015.
15. Flo, K.; Hansen, M.; Orbo, A.; Kjorstad, K.E.; Maltau, J.M.; Sager, G. Effect of probenecid, verapamil and progesterone on the concentration-dependent and temperature-sensitive human erythrocyte uptake and export of guanosine 3', 5' cyclic monophosphate (cGMP). Scand. J. Clin. Lab. Invest., 1995, 55, 715-721.
16. Ballerini, P.; Di Iorio, P.; Ciccarelli, R.; Nargi, E.; D'Alimonte, I.; Traversa, U.; Rathbone, M. P.; Caciagli, F. Glial cells express multiple ATP binding cassette proteins which are involved in ATP release. Neuroreport, 2002, 13, 1789-1792.
17. Darby, M.; Kuzmiski, J.B.; Panenka, W.; Feighan, D.; MacVicar, B.A. ATP released from astrocytes during swelling activates chloride channels. J. Neurophysiol., 2003, 89, 1870-1877.
18. Di Virgilio, F.; Steinberg, T. H.; Silverstein, S. C. Inhibition of Fura-2 sequestration and secretion with organic anion transport blockers. Cell Calcium, 1990, 11, 57-62.
19. Perwitasari, O.; Yan, X.; Johnson, S.; White, C.; Brooks, P.; Tompkins, S. M.; Tripp, R. A. Targeting organic anion transporter 3 with probenecid as a novel anti-influenza a virus strategy. Antimicrob. Agents Chemother., 2013, 57, 475-483.
20. Ilett, K. F.; Hackett, L. P.; Ingle, B.; Bretz, P. J. Transfer of probenecid and cephalexin into breast milk. Ann. Pharmacother., 2006, 40, 986-989.
21. Sweet, D. H. Organic anion transporter (Slc22a) family members as mediators of toxicity. Toxicol. Appl. Pharmacol., 2005, 204, 198-215.
22. Kojima, R.; Sekine, T.; Kawachi, M.; Cha, S. H.; Suzuki, Y.; Endou, H. Immunolocalization of multispecific organic anion transporters, OAT1, OAT2, and OAT3, in rat kidney. J. Am. Soc. Nephrol., 2002, 13, 848-857.
23. El-Sheikh, A.A.; Masereeuw, R.; Russel, F.G. Mechanisms of renal anionic drug transport. Eur. J. Pharmacol., 2008, 585, 245-255.
24. Bahn, A.; Ljubojevic, M.; Lorenz, H.; Schultz, C.; Ghebremedhin, E.; Ugele, B.; Sabolic I.; Burckhardt, G.; Hagos, Y. Murine renal organic anion transporters mOAT1 and mOAT3 facilitate the transport of neuroactive tryptophan metabolites. Am. J. Physiol. Cell Physiol., 2005, 289, C1075-C1084.
25. Nagata, Y.; Kusuhara, H.; Imaoka, T.; Endou, H.; Sugiyama, Y. Involvement of rat organic anion transporter 3 in the uptake of an organic herbicide, 2, 4-dichlorophenoxyacetate, by the isolated rat choroid plexus. J. Pharm. Sci., 2004, 93, 2724-2732.
26. Sykes, D.; Sweet, D. H.; Lowes, S.; Nigam, S. K.; Pritchard, J. B.; Miller, D. S. Organic anion transport in choroid plexus from wild-type and organic anion transporter 3 (Slc22a8)-null mice. Am. J. Physiol. Renal Physiol., 2004, 286, F972-F978.
27. Miyajima, M.; Kusuhara, H.; Fujishima, M.; Adachi, Y.; Sugiyama, Y. Organic anion transporter 3 mediates the efflux transport of an amphipathic organic anion, dehydroepiandrosterone sulfate, across the blood-brain barrier in mice. Drug Metab. Dispos., 2011, 39, 814-819.
28. Chiba, S.; Ikawa, T.; Takeshita, H.; Ichiba, K.; Sagi, M.; Mukai, T.; Anzai, N. Interactions of human organic anion transporter 1 (hOAT1) with substances associated with forensic toxicology. Leg. Med. (Tokyo), 2011, 13, 180-185.
29. Mandal, G.; Sarkar, A.; Saha, P.; Singh, N.; Sundar, S.; Chatterjee, M. Functionality of drug efflux pumps in antimonial resistant Leishmania donovani field isolates. Indian J. Biochem. Biophys., 2009, 46, 86-92.
30. Roch-Ramel, F. Renal transport of organic anions. Curr. Opin. Nephrol. Hypertens., 1998, 7, 517-524.
31. Sisodiya, S. M.; Lin, W. R.; Harding, B. N.; Squier, M. V.; Thom, M. Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy. Brain, 2002, 125, 22-31.
32. van der Valk, P.; van Kalken, C. K.; Ketelaars, H.; Broxterman, H. J.; Scheffer, G.; Kuiper, C. M.; Tsuruo, T.; Lankelma, J.; Meijer, C. J.; Pinedo, H. M. Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Analysis with 3 monoclonal antibodies recognizing different epitopes of the P-glycoprotein molecule. Ann. Oncol., 1990, 1, 56-64.
33. Diena, T.; Melani, R.; Caci, E.; Pedemonte, N.; Sondo, E.; Zegarra-Moran, O.; Galietta, L. J. Block of CFTR-dependent chloride currents by inhibitors of multidrug resistance-associated proteins. Eur. J. Pharmacol., 2007, 560, 127-131.
34. van Vliet, E. A.; Redeker, S.; Aronica, E.; Edelbroek, P. M.; Gorter, J. A. Expression of multidrug transporters MRP1, MRP2, and BCRP shortly after status epilepticus, during the latent period, and in chronic epileptic rats. Epilepsia, 2005, 46, 1569-1580.
35. Potschka, H.; Fedrowitz, M.; Löscher, W. Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity. J. Pharmacol. Exp. Ther., 2003, 306, 124-131.
36. Piwnica-Worms, D.; Kesarwala, A. H.; Pichler, A.; Prior, J. L.; Sharma, V. Single photon emission computed tomography and positron emission tomography imaging of multi-drug resistant P-glycoprotein--monitoring a transport activity important in cancer, blood-brain barrier function and Alzheimer's disease. NeuroimagingClin. N. Am., 2006, 16, 575-589.
37. Perrone, M. G.; Inglese, C.; Berardi, F.; Leopoldo, M.; Perrone, R.; Colabufo, N. A. Comparative evaluation of two dye probes in the rat everted gut sac model for unambiguous classification of P-gp substrate and inhibitor. J. Pharmacol. Toxicol. Methods, 2013, 67(1), 5-8.
38. Vriens, J.; Appendino, G.; Nilius, B. Pharmacology of vanilloid transient receptor potential cation channels. Mol. Pharmacol., 2009, 75, 1262-1279.
39. Cortright, D.N.; Szallasi, A. TRP channels and pain. Curr. Pharm. Des., 2009, 15, 1736-1749.
40. Kanzaki, M.; Zhang, Y. Q.; Mashima, H.; Li, L.; Shibata, H.; Kojima, I. Translocation of a calcium-permeable cation channel induced by insulin-like growth factor-I. Nat. Cell Biol., 1999, 1, 165-170.
41. Qin, N.; Neeper, M. P.; Liu, Y.; Hutchinson, T. L.; Lubin, M. L.; Flores, C. M. TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons. J. Neurosci., 2008, 28, 6231-6238.
42. Silverman, W.; Locovei, S.; Dahl, G. Probenecid, a gout remedy, inhibits pannexin 1 channels. Am. J. Physiol. Cell Physiol., 2008, 295, C761-C767.
43. Dahl, G.; Locovei, S. Pannexin: to gap or not to gap, is that a question? IUBMB Life, 2006, 58, 409-419.
44. Bargiotas, P.; Krenz, A.; Monyer, H.; Schwaninger, M. Functional outcome of pannexin-deficient mice after cerebral ischemia. Channels (Austin), 2012, 6, 453-456.
45. Billaud, M.; Lohman, A. W.; Straub, A. C.; Looft-Wilson, R.; Johnstone, S. R.; Araj, C. A.; Best, A. K.; Chekeni, F. B.; Ravichandran, K. S.; Penuela, S.; Laird, D. W.; Isakson, B. E. Pannexin1 regulates 1-adrenergic receptor-mediated vasoconstriction. Circ. Res., 2011, 109, 80-85.
46. Li, A.; Leung, C.T.; Peterson-Yantorno, K.; Mitchell, C.H.; Civan, M.M. Pathways for ATP release by bovine ciliary epithelial cells, the initial step in purinergic regulation of aqueous humor inflow. Am. J. Physiol. Cell Physiol., 2010, 299, C1308-C1317.
47. Prochnow, N.; Abdulazim, A.; Kurtenbach, S.; Wildförster, V.; Dvoriantchikova, G.; Hanske, J.; Petrasch-Parwez, E.; Shestopalov, V. I.; Dermietzel, R.; Manahan-Vaughan, D.; Zoidl, G. Pannexin1 stabilizes synaptic plasticity and is needed for learning. PLoS One, 2012, 7, e51767.
48. Fontainhas, A.M.; Wang, M.; Liang, K.J., Chen, S.; Mettu, P.; Damani, M.; Fariss, R.N.; Li, W., Wong, W.T. Microglial morphology and dynamic behavior is regulated by ionotropic glutamatergic and GABAergic neurotransmission. PLoS One, 2011, 6, e15973.
49. Allan, S.M.; Tyrrell, P.J.; Rothwell, N.J. Interleukin-1 and neuronal injury. Nat. Rev. Immunol., 2005, 5, 629-640.
50. Dahl, G.; Keane, R.W. Pannexin: from discovery to bedside in 11±4 years? Brain Res., 2012, 1487, 150-159.
51. Selen, A.; Amidon, G. L.; Welling, P. G. Pharmacokinetics of probenecid following oral doses to human volunteers. J. Pharm. Sci., 1982, 71, 1238-1242.
52. Cunningham, R. F.; Israili, Z. H.; Dayton, P. G. Clinical pharmacokinetics of probenecid. Clin. Pharmacokinet., 1981, 6, 135-151.
53. Israili, Z. H., Percel, J. M.; Cunningham, R. F.; Dayton, P. G.; Yü, T. F.; Gutman, A. B.; Long, K. R.; Long, R.C. Jr.; Goldstein, J. H. Metabolites of probenecid. Chemical, physical, and pharmacological studies. J. Med. Chem., 1972, 15, 709-713.
54. Boger, W. P.; Strickland, S. C. Probenecid (benemid); its uses and side-effects in 2, 502 patients. AMA Arch. Intern. Med., 1955, 95, 83-92.
55. Sosler, S. D.; Behzad, O.; Garratty, G.; Lee, C. L.; Postoway, N.; Khomo, O. Immune hemolytic anemia associated with probenecid. Am. J. Clin. Pathol., 1985, 84, 391-394.
56. Kickler, T. S.; Buck, S.; Ness, P.; Shirey, R. S.; Sholar, P. W. Probenecid induced immune hemolytic anemia. J. Rheumatol., 1986, 13, 208-209.
57. Izzedine, H.; Brocheriou, I.; Becart, J.; Deray, G. Probenecid-induced membranous nephropathy. Nephrol. Dial. Transplant, 2007, 22, 2405-2406.
58. Ferris, T. F.; Morgan, W. S.; Levitin, H. Nephrotic syndrome caused by probenecid. N. Engl. J. Med., 1961, 265, 381-383.
59. Scott, J. T.; O'Brien, P. K. Probenecid, nephrotic syndrome, and renal failure. Ann. Rheum. Dis., 1968, 27, 249-252.
60. Sokol, A.; Bashner, M. H.; Okun, R. Nephrotic syndrome caused by probenecid. JAMA, 1967, 199, 43-44.
61. Hertz, P.; Yager, H.; Richardson, J. A. Probenecid-induced nephrotic syndrome. Arch. Pathol., 1972, 94, 241-243.
62. Reynolds, E. S.; Schlant, R. C.; Gonick, H. C.; Dammin, G. J. Fatal massive necrosis of the liver as a manifestation of hypersensitivity to probenecid. N. Engl. J. Med., 1957, 256, 592-596.
63. Austrian, C. R., Boger, W. P. Sensitization and subsequent desensitization to probenecid (benemid). AMA Arch. Intern. Med., 1956, 98, 505-509.
64. Hillecke, N. A. Acute anaphylactoid reaction to probenecid. JAMA, 1965, 193, 740.
65. Goodrich, J. T. Treatment of gonorrhea in pregnancy. Sex Transm. Dis., 1979, 6, 168-173.
66. Petty, B. G.; Kornhauser, D. M., Lietman, P. S. Zidovudine with probenecid: a warning. Lancet, 1990, 335, 1044-1045.
67. Polis, M. A.; Spooner, K. M., Baird, B. F.; Manischewitz, J. F.; Jaffe, H. S.; Fisher, P. E.; Falloon, J.; Davey, R.T. Jr.; Kovacs, J. A.; Walker, R. E. Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria. Antimicrob. Agents Chemother., 1995, 39, 882-886.
68. Lalezari, J. P.; Drew, W. L.; Glutzer, E.; James, C.; Miner, D.; Flaherty, J.; Fisher, P. E.; Cundy, K.; Hannigan, J; Martin, J. C. (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue. J. Infect. Dis., 1995, 171, 788-796.
69. Myers, K. W.; Katial, R. K.; Engler, R. J. Probenecid hypersensitivity in AIDS: a case report. Ann. Allergy Asthma Immunol., 1998, 80, 416-418.
70. Hirshfeld, A.B.; Getachew, A.; Sessions, J. Drug doses. In: Siberry GK, Iannone R, eds. The Harriet Lane handbook. A manual for pediatric house officers. St. Louis:Mosby, 2000, 825-826.
71. Massudi, H.; Grant, R.; Guillemin, G.J.; Braidy, N. NAD+ metabolism and oxidative stress: the golden nucleotide on a crown of thorns. Redox Rep., 2012, 17, 28-46.
72. Schwarcz, R.; Bruno, J.P.; Muchowski, P.J.; Wu, H. Kynurenines in the mammalian brain: when physiology meets pathology. Nat. Rev. Neurosci., 2012, 13, 465-477.
73. Yu, P.; Di Prospero, N.A.; Sapko, M.T.; Cai, T.; Chen, A.; Melendez-Ferro, M.; Du, F.; Whetsell, W.O.Jr.; Guidetti, P.; Schwarcz, R.; Tagle, D.A. Biochemical and phenotypic abnormalities in kynurenine aminotransferase II-deficient mice. Mol. Cell. Biol., 2004, 24, 6919-6930.
74. Moroni, F.; Russi, P.; Lombardi, G.; Beni, M.; Carlà, V. Presence of kynurenic acid in the mammalian brain. J. Neurochem., 1988, 51, 177-180.
75. Swartz, K. J.; During, M. J.; Freese, A.; Beal, M. F. Cerebral synthesis and release of kynurenic acid: an endogenous antagonist of excitatory amino acid receptors. J. Neurosci., 1990, 10, 2965-2973.
76. Miller, J.M.; MacGarvey, U.; Beal, M.F. The effect of peripheral loading with kynurenine and probenecid on extracellular striatal kynurenic acid concentrations. Neurosci. Lett., 1992, 146, 115-118.
77. Hilmas, C.; Pereira, E.F.R.; Alkondon, M.; Rassoulpour, A.; Schwarcz, R.; Albuquerque, E.X. The brain metabolite kynurenic acid inhibits 7 nicotinic receptor activity and increases non a7 nicotinic receptor expression: physiopathological implications. J. Neurosci., 2001, 21, 7463-7473.
78. Moroni, F.; Cozzi, A.; Sili, M.; Mannaioni, G. Kynurenic acid: a metabolite with multiple actions and multiple targets in brain and periphery. J. Neural Transm., 2012, 119, 133-139.
79. Kessler, M.; Terramani, T.; Lynch, G.; Baudry, M. A glycine site associated with NMDA receptors: characterisation and identification of a new class of antagonist. J. Neurochem., 1989, 52, 1319-1328.
80. Carpenedo, R.; Pittaluga, A.; Cozzi, A.; Attucci, S.; Galli, A.; Raiteri, M.; Moroni, F. Presynaptic kynurenate-sensitive receptors inhibit glutamate release. Eur. J. Neurosci., 2001, 13, 2141-2147.
81. Perkins, M.N.; Stone, T.W. Specificity of kynurenic acid as an antagonist of synaptic transmission in rat hippocampal slices. Neurosci. Lett., 1982, 18, 432.
82. Ganong, A.H.; Lanthorn, T.H.; Cotman, C.W. Kynurenic acid inhibits synaptic and acidic amino acid-induced responses in the rat hippocampus and spinal cord. Brain Res., 1983, 273, 170-174.
83. Foster, A.; Vezzani, A.; French, E.D.; Schwarcz, R. Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid. Neurosci. Lett., 1984, 48, 273-278.
84. Albuquerque, E.X.; Schwarcz, R. Kynurenic acid as an antagonist of a7 nicotinic acetylcholine receptors in the brain: Facts and challenges. Biochem. Pharmacol. 2013, 85, 1027-1032.
85. Wang, J.; Simonavicius, N.; Wu, X.; Swaminath, G.; Reagan, J.; Tian, H. Kynurenic acid as a gand for orphan G protein-coupled receptor GPR35. J. Biol. Chem., 2006, 281, 22021-22028.
86. Ohshiro, H.; Tonai-Kachi, H.; Ichikawa, K. GPR35 is a functional receptor in rat dorsal root ganglion neurons. Biochem. Biophys. Res. Commun., 2008, 365, 344-348.
87. Denison, M.S.; Nagy, S.R. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu. Rev. Pharmacol. Toxicol., 2003, 43, 309-334.
88. Nguyen, N. T.; Kimura, A.; Nakahama, T.; Chinen, I.; Masuda, K.; Nohara, K.; Fujii-Kuriyama, Y.; Kishimoto, T. Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc. Natl. Acad. Sci. USA, 2010, 107, 19961-19966.
89. Opitz, C. A.; Litzenburger, U. M.; Sahm, F.; Ott, M.; Tritschler, I.; Trump, S.; Schumacher, T.; Jestaedt, L.; Schrenk, D.; Weller, M.; Jugold, M.; Guillemin, G. J.; Miller, C. L.; Lutz, C.; Radlwimmer, B.; Lehmann, I.; von Deimling, A.; Wick, W.; Platten, M. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature, 2011, 478, 197-203.
90. Stevens, E.A.; Mezrich, J.D.; Bradfield, C.A. The aryl hydrocarbon receptor: a perspective on potential roles in the immune system. Immunology, 2009, 127, 299-311.
91. Lapin, I.P. Depressor effect of kynurenine and its metabolites in rats. Life Sci., 1976, 19, 1479-1484.
92. Lapin, I.P. Experimental studies on kynurenine as neuroactive tryptophan metabolites: past, present and future. Trends Pharmacol. Sci., 1980, 1, 410-413.
93. Turski, W.A.; Schwarcz, R. On the disposition of intrahippocampally injected kynurenic acid in the rat. Exp. Brain Res., 1988, 71, 563-567.
94. Fatokun, A. A.; Smith, R. A.; Stone, T. W. Resistance to kynurenic acid of the NMDA receptor-dependent toxicity of 3-nitropropionic acid and cyanide in cerebellar granule neurons. Brain Res., 2008, 1215, 200-207.
95. Lugo-Huitrón, R.; Blanco-Ayala, T.; Ugalde-Muñiz, P.; Carrillo-Mora, P.; Pedraza-Chaverrí, J.; Silva-Adaya, D.; Maldonado, P. D.; Torres, I.; Pinzón, E.; Ortiz-Islas, E.; López, T.; García, E.; Pineda, B.; Torres-Ramos, M.; Santamaría, A.; La Cruz, V. P. On the antioxidant properties of kynurenic acid: free radical scavenging activity and inhibition of oxidative stress. Neurotoxicol. Teratol., 2011, 33, 538-547.
96. Rios, C.; Santamaria, A. Quinolinic acid is a potent lipid peroxidant in rat brain homogenates. Neurochem. Res., 1991, 16, 1139-1143.
97. Heyes, M.P.; Saito, K.; Major, E.O.; Milstien, S.; Markey, S.P.; Vickers, J.H. A mechanism of quinolinic acid formation by brain in inflammatory neurological disease. Attenuation of synthesis from L-tryptophan by 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate. Brain, 1993, 116, 1425-1450.
98. Knyihár-Csillik, E.; Chadaide, Z.; Okuno, E.; Krisztin-Péva, B.; Toldi, J.; Varga, C.; Molnár, A.; Csillik, B.; Vécsei, L. Kynurenine aminotransferase in the supratentorial dura mater of the rat: effect of stimulation of the trigeminal ganglion. Exp. Neurol., 2004, 186, 242-247.
99. Tiszlavicz, Z.; Németh, B.; Fülöp, F.; Vécsei, L.; Tápai, K.; Ocsovszky, I.; Mándi, Y. Different inhibitory effects of kynurenic acid and a novel kynurenic acid analogue on tumour necrosis factor-(TNF-) production by mononuclear cells, HMGB1 production by monocytes and HNP1-3 secretion by neutrophils. Naunyn Schmiedebergs Arch. Pharmacol., 2011, 383, 447-455.
100. Muller, N.; Schwarz, M. Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. Neurotox. Res., 2006, 10, 131-148.
101. Schwarcz, R.; Rassoulpour, A.; Wu, H.Q.; Medoff, D.; Tamminga, C.A.; Roberts, R.C. Increased cortical kynurenate content in schizophrenia. Biol. Psychiatry, 2001, 50, 521-30.
102. Stone, T.W.; Stoy, N.; Darlington, L.G. An expanding range of targets for kynurenine metabolites of tryptophan. Trends Pharmacol. Sci. 2013, 34, 136-143.
103. Világi, I.; Klapka, N.; Luhmann, H. J. Optical recording of spreading depression in rat neocortical slices. Brain Res., 2001, 898, 288-296.
104. Németh, H.; Robotka, H.; Kis, Z.; Rózsa, E.; Janáky, T.; Somlai, C.; Marosi, M.; Farkas, T.; Toldi, J.; Vécsei, L. Kynurenine administered together with probenecid markedly inhibits pentylenetetrazol-induced seizures. An electrophysiological and behavioural study. Neuropharmacology, 2004, 47, 916-925.
105. Vamos, E.; Pardutz, A.; Klivenyi, P.; Toldi, J.; Vecsei, L. The role of kynurenines in disorders of the central nervous system: possibilities for neuroprotection. J. Neurol. Sci., 2009, 283, 21-27.
106. Stone, T.W.; Forrest, C.M.; Darlington, L.G. Kynurenine pathway inhibition as a therapeutic strategy for neuroprotection. FEBS J., 2012, 279, 1386-1397.
107. Tan, L.; Yu, J. -T.; Tan, L. The kynurenine pathway in neurodegenerative diseases: Mechanistic and therapeutic considerations. J. Neurol. Sci., 2012, 323, 1-8.
108. Fukui, S.; Schwarcz, R.; Rapoport, S.I.; Takada, Y.; Smith, Q.R. Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J. Neurochem., 1991, 56, 2007-2017.
109. Gál, E. M.; Sherman, A. D. Synthesis and metabolism of L-kynurenine in rat brain. J. Neurochem., 1978, 30, 607-613.
110. Uwai, Y.; Honjo, H.; Iwamoto, K. Interaction and transport of kynurenic acid via human organic anion transporters hOAT1 and hOAT3. Pharmacol. Res., 2012, 65, 254-260.
111. Chauvel, V.; Vamos, E.; Pardutz, A.; Vecsei, L.; Schoenen, J.; Multon, S. Effect of systemic kynurenine on cortical spreading depression and its modulation by sex hormones in rat. Exp. Neurol., 2012, 236, 207-214.
112. Bové, J.; Prou, D.; Perier, C.; Przedborski, S. Toxin-induced models of Parkinson's disease. NeuroRx, 2005, 2, 484-494.
113. Beal, M.F. Experimental models of Parkinson's disease. Nat. Rev. Neurosci., 2001, 2, 325-334.
114. Blandini, F.; Armentero, M. T. Animal models of Parkinson's disease. FEBS J., 2012, 279, 1156-1166.
115. Silva-Adaya, D.; Pérez De La Cruz, V; Villeda-Hernández, J; Carrillo-Mora, P; González-Herrera, I.G.; García, E.; Colín-Barenque, L.; Pedraza-Chaverrí, J.; Santamaría, A. Protective effect of L-kynurenine and probenecid on 6-hydroxydopamine-induced striatal toxicity in rats: implications of modulating kynurenate as a protective strategy. Neurotoxicol. Teratol., 2011, 33, 303-312.
116. Miranda, A.F.; Boegman, R.J.; Beninger, R.J.; Jhamandas K. Protection against quinolinic acid-mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid. Neuroscience, 1997, 78, 967-75.
117. Cavallucci, V.; Ferraina, C.; D'Amelio, M. Key role of mitochondria in Alzheimer's disease synaptic dysfunction. Curr. Pharm. Des., 2013 [Epub ahead of print].
118. Niranjan, R. Molecular basis of etiological implications in Alzheimer's disease: focus on neuroinflammation. Mol. Neurobiol., 2013 [Epub ahead of print].
119. Mehta, A.; Prabhakar, M.; Kumar, P.; Deshmukh, R.; Sharma, P.L. Excitotoxicity: bridge to various triggers in neurodegenerative disorders. Eur. J. Pharmacol., 2013, 698, 6-18.
120. Reitz, C. Alzheimer's disease and the amyloid cascade hypothesis: a critical review. Int. J. Alzheimer's Dis., 2012, 2012, 369808.
121. Carrillo-Mora, P.; Méndez-Cuesta, L.A.; Pérez-De La Cruz, V; Fortoul-van Der Goes, T.I; Santamaría A. Protective effect of systemic L-kynurenine and probenecid administration on behavioural and morphological alterations induced by toxic soluble amyloid beta (25-35) in rat hippocampus. Behav. Brain Res., 2010, 210, 240-50.
122. Santamaría, A.; Ríos, C.; Solís-Hernández, F.; Ordaz-Moreno, J.; González-Reynoso, L.; Altagracia, M.; Kravzov, J. Systemic DL-kynurenine and probenecid pretreatment attenuates quinolinic acid-induced neurotoxicity in rats. Neuropharmacology, 1996, 35, 23-28.
123. Harris, C. A.; Miranda, A. F.; Tanguay, J. J.; Boegman, R. J.; Beninger, R. J.; Jhamandas, K. Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid. Br. J. Pharmacol., 1998, 124, 391-399.
124. Vamos, E.; Voros, K.; Zadori, D.; Vecsei, L.; Klivenyi P. Neuroprotective effects of probenecid in a transgenic animal model of Huntington's disease. J. Neural Transm., 2009, 116, 1079-1086.
125. Russell, M. B.; Olesen, J. Migrainous disorder and its relation to migraine without aura and migraine with aura. A genetic epidemiological study. Cephalalgia, 1996, 16, 431-435.
126. Rasmussen, B.K.; Olesen, J. Migraine with aura and migraine without aura: an epidemiological study. Cephalalgia, 1992, 12, 221-228.
127. Tfelt-Hansen, P. C. History of migraine with aura and cortical spreading depression from 1941 and onwards. Cephalalgia, 2010, 30, 780-792.
128. Brennan, K. C.; Romero-Reyes, M.; López-Valdés, H. E.; Arnold, A. P.; Charles, A. C. Reduced threshold for cortical spreading depression in female mice. Ann. Neurol., 2007, 61, 603-606.
129. Eliot, A.C.; Kirsch, J.F. Pyridoxal phosphate enzymes: mechanistic, structural, and evolutionary considerations. Annu. Rev. Biochem., 2004, 73, 383-415.
130. Taylor, D. L.; Urenjak, J.; Zilkha, E.; Obrenovitch, T. P. Effects of probenecid on the elicitation of spreading depression in the rat striatum. Brain Res., 1997, 764, 117-125.
131. Kuhr, W. G.; Korf, J. Extracellular lactic acid as an indicator of brain metabolism: continuous on-line measurement in conscious, freely moving rats with intrastriatal dialysis. J. Cereb. Blood Flow Metab., 1988, 8, 130-137.
132. Gelhaus, S.L.; Gilad, O.; Hwang, W.T.; Penning, T.M.; Blair, I.A. Multidrug resistance protein (MRP) 4 attenuates benzo[a]pyrene-mediated DNA-adduct formation in human bronchoalveolar H358 cells. Toxicol. Lett., 2012, 209, 58-66.
133. Wong, C.H.; Crack, P.J. Modulation of neuro-inflammation and vascular response by oxidative stress following cerebral ischemia-reperfusion injury. Curr. Med. Chem., 2008, 15, 1-14.
134. Sas, K.; Robotka, H.; Rózsa, E.; Agoston, M.; Szénási, G.; Gigler, G.; Marosi, M.; Kis, Z.; Farkas, T.; Vécsei, L.; Toldi, J. Kynurenine diminishes the ischemia-induced histological and electrophysiological deficits in the rat hippocampus. Neurobiol. Dis., 2008, 32, 302-308.
135. Robotka, H.; Sas, K.; Agoston, M.; Rózsa, E.; Szénási, G.; Gigler, G.; Vécsei, L.; Toldi, J. Neuroprotection achieved in the ischaemic rat cortex with L-kynurenine sulphate. Life Sci., 2008, 82, 915-919.
136. Gigler, G.; Szénási, G.; Simó, A.; Lévay, G.; Hársing, L.G. Jr.; Sas, K.; Vécsei, L.; Toldi, J. Neuroprotective effect of L-kynurenine sulfate administered before focal cerebral ischemia in mice and global cerebral ischemia in gerbils. Eur. J. Pharmacol., 2007, 564, 116-122.
137. Nozaki, K.; Beal, M. F. Neuroprotective effects of L-kynurenine on hypoxia-ischemia and NMDA lesions in neonatal rats. J. Cereb. Blood Flow Metab., 1992, 12, 400-407.
138. Kobow, K.; Auvin, S.; Jensen, F.; Löscher, W.; Mody, I.; Potschka, H.; Prince, D.; Sierra, A.; Simonato, M.; Pitkänen, A.; Nehlig A.; Rho, J.M. Finding a better drug for epilepsy: antiepileptogenesis targets. Epilepsia, 2012, 53, 1868-1876.
139. Vécsei, L.; Miller, J.; MacGarvey, U.; Beal, M.F. Kynurenine and probenecid inhibit pentylenetetrazol-and NMDLA-induced seizures and increase kynurenic acid concentrations in the brain. Brain Res. Bull., 1992, 28, 233-238.